Merck, N0289-50MG, Nafamostat mesylate

Application
Nafamostat mesylate has been used:
as a serine protease inhibitor to study its effects on proteolytic degradation of therapeutic proteins recombinantly expressed in Chinese hamster ovary (CHO)-K1-derived cells
to stop complement activation to validate the assay for murine C3 fragments
as a serine protease inhibitor to study its effects on house dust mite extract evoked Ca2+ entry

Biochem/physiol Actions
Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation.
Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor.
Nafamostat mesylate is used in the treatment of disseminated intravascular coagulation (DIC), pancreatitis, and systemic inflammatory response syndrome. It can block the proliferation, adhesion, and invasion of cancer cells and repress tumor progression in animal models. Nafamostat mesylate is involved in the development of immune activity. In combination with favipiravir, nafamostat mesylate may block virus entry and replication, and inhibit the pathogenic host response. This combination treatment might be effective for critically ill Covid-19 patients.